Figure 6.

EDC-CD20 has dose dependent antitumor activity that surpasses Rituximab in DLBCL tumor models. Data are plotted as group mean tumor volumes post tumor implant, with standard error of the mean (SEM) which are indicated by vertical bars. (a) CB17SCID mice (n = 6 per group) bearing s.c. SU-DHL-4 xenograft tumors of an average size of 250 mm³ were treated with vehicle (dashed line) EDC-CD20 (circle) or Rituximab (diamond) at 5 mg/kg using the dosing schedule of q6dx2 via i.p. injection. (b) CB17SCID mice (n = 6 per group) bearing s.c. SU-DHL-4 xenograft tumors of an average size of 250 mm³ were treated with either vehicle (dashed line) or EDC-CD20 dosed at 0.5 mg/kg (triangle), 1.5 mg/kg (square), or 5 mg/kg (circle) using the dosing schedule of q6dx2 via i.p. injection.